[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563022":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":52,"locations":58,"responsibleParty":130,"collaborators":26,"id":133,"slug":26,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":26,"eligibilityCriteria":138,"healthyVolunteers":134,"sex":139,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":26,"studyType":145,"phases":146,"briefSummary":148,"conditions":149,"keywords":26,"overallStatus":60,"whyStopped":26,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"Xijing Hospital of Digestive Diseases","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"The ursodeoxycholic acid group","EXPERIMENTAL","Patients in the ursodeoxycholic acid group will receive oral ursodeoxycholic acid at a dosage of 250 mg three times daily for 6 months.",[13],"Drug: Ursodeoxycholic Acid",{"label":15,"type":16,"description":17,"interventionNames":18},"The placebo group","PLACEBO_COMPARATOR","Patients in the placebo group will receive oral placebo at a dosage of 250 mg three times daily for 6 months.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ursodeoxycholic Acid","Subjects will be instructed to take one capsule (250mg) of ursodeoxycholic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Subjects will be instructed to take one capsule (250mg) of placebo three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.",[15],[32,36,40,43,46,49],{"name":33,"affiliation":34,"role":35},"Yongquan Shi, PhD","Air Force Military Medical University, China","STUDY_CHAIR",{"name":37,"affiliation":38,"role":39},"Xinzhao Wang","989 Hospital of PLA Joint Logistics Support Force","PRINCIPAL_INVESTIGATOR",{"name":41,"affiliation":42,"role":39},"Kun Zhuang","Xi'an Central Hospital",{"name":44,"affiliation":45,"role":39},"Zhufang Ma","Hanzhong 3201 Hospital",{"name":47,"affiliation":48,"role":39},"Yuan Gao","Ankang Central Hospital",{"name":50,"affiliation":51,"role":39},"Long Zou","Shangluo Central Hospital",[53],{"name":54,"role":55,"phone":56,"phoneExt":26,"email":57},"Yongquan Shi","CONTACT","0086 + 02984771515","shiyquan@fmmu.edu.cn",[59,74,86,97,109,122],{"facility":38,"status":60,"city":61,"state":62,"zip":26,"country":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"RECRUITING","Pingdingshan","Henan","China",{"type":65,"coordinates":66},"Point",[67,68],113.31554,33.73091,{"lat":68,"lon":67},[71],{"name":37,"role":55,"phone":72,"phoneExt":26,"email":73},"0375-3843070","xinzhw66@163.com",{"facility":48,"status":60,"city":75,"state":76,"zip":26,"country":63,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Ankang","Shaanxi",{"type":65,"coordinates":78},[79,80],109.01722,32.68,{"lat":80,"lon":79},[83],{"name":47,"role":55,"phone":84,"phoneExt":26,"email":85},"0915-2391384","gaoyuan015@163.com",{"facility":45,"status":60,"city":87,"state":76,"zip":26,"country":63,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Hanzhong",{"type":65,"coordinates":89},[90,91],107.02214,33.07507,{"lat":91,"lon":90},[94],{"name":44,"role":55,"phone":95,"phoneExt":26,"email":96},"0916-2380433","369852677@qq.com",{"facility":51,"status":60,"city":98,"state":76,"zip":26,"country":63,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Shangluo",{"type":65,"coordinates":100},[101,102],109.93056,33.86667,{"lat":102,"lon":101},[105],{"name":106,"role":55,"phone":107,"phoneExt":26,"email":108},"Ya Lan","0914-2360126","lylan2013@163.com",{"facility":110,"status":60,"city":111,"state":76,"zip":112,"country":63,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Xijing hospital","Xi'an","710032",{"type":65,"coordinates":114},[115,116],108.92861,34.25833,{"lat":116,"lon":115},[119],{"name":120,"role":55,"phone":121,"phoneExt":26,"email":57},"Yongquan Shi Shi","029-84771515",{"facility":42,"status":60,"city":111,"state":76,"zip":26,"country":63,"cosmosGeoPoint":123,"geoPoint":125,"contacts":126},{"type":65,"coordinates":124},[115,116],{"lat":116,"lon":115},[127],{"name":41,"role":55,"phone":128,"phoneExt":26,"email":129},"029-62812259","1033077816@qq.com",{"type":131,"investigatorFullName":54,"investigatorTitle":132,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Professor","100563022",false,"NCT06610760","Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia","Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia: A Multicenter, Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* patients aged from 18 to 75 years old.\n* patients with OLGIM stage Ⅱ-Ⅳ diagnosed by upper gastrointestinal endoscopy and histopathological examination within the last 3 months.\n* patients without Helicobacter pylori infection, including patients who had successful Helicobacter pylori eradication before enrollment.\n\nExclusion Criteria:\n\n* a history of regular use (defined as at least once per week) of non-steroidal anti-inflammatory drugs (NSAIDs) and\u002For statins.\n* a history of stomach surgery (including endoscopic submucosal dissection and endoscopic mucosal resection) or previously diagnosed malignant tumor.\n* a history of heart failure, renal failure, liver cirrhosis or chronic hepatic failure; patients with contraindications or allergies to the drugs in this study.\n* breastfeeding or pregnancy.\n* a history of substance abuse or alcohol abuse within the past one year.\n* patients with severe mental illness.\n* refusal to undergo drug treatment.\n* refusal to sign informed consent.","ALL","18 Years","75 Years",{"count":143,"type":144},196,"ESTIMATED","INTERVENTIONAL",[147],"PHASE4","The goal of this clinical trial is to investigate the efficacy of ursodeoxycholic acid in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. It will also learn about the safety of ursodeoxycholic acid. The main questions it aims to answer are:\n\nDoes ursodeoxycholic acid promote the regression of IM in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking ursodeoxycholic acid? Researchers will compare ursodeoxycholic acid to a placebo (a look-alike substance that contains no drug) to see if ursodeoxycholic acid is effective in treating gastric intestinal metaplasia.\n\nParticipants will:\n\nTake ursodeoxycholic acid or a placebo every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.",[150],"Gastric Intestinal Metaplasia","2025-12-04",{"date":153,"type":154},"2025-12-05","ACTUAL",{"date":156,"type":154},"2024-11-12",{"date":158,"type":144},"2026-10-31",{"name":54,"class":6},6]